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I. Research background and relevance of the 
topic  
 
Biopharmaceutical drugs have been available for more 
than 20 years. The agents revolutionised the treatment of 
chronic diseases in several areas of medicine; however, 
these have an increased effect on the societies due to 
their high costs, thus the benefits also bring challenges 
and concerns about their value for money. Therefore 
there is an increased importance about health economic 
analysis where we analyse the unit expenses and also the 
unit health gain. Biologics represent only about 2-5 
percent of the drug budget, but this is also a fast-growing 
segment of the pharmaceutical market. Biological 
treatments are usually expensive and lead to increasing 
pharmaceutical expenditures. On one hand, there is a 
clinical demand for wider use of biologics, and thus 
preference for the increasing use of these drugs. On the 
other hand, there are also certain limitations in terms of 
resource restrictions on financing (affordability), 
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meaning that the number of patients clinically eligible for 
biologic therapy is higher than the financing capacity of 
the funder. Therefore a gap exists between what is 
therapeutically possible and what is economically 
affordable. 
Despite the centralised drug registration and clinical 
guidelines on the European Union level, there is variation 
in financing practices and treatment, and also in the 
patient’s access to these agents across Europe. The 
Central Eastern European (CEE) countries cannot be 
considered as a homogeneous group either from this 
perspective, but the financial burden of biological 
treatment puts a common pressure on the health care 
systems in these countries. Furthermore, the growth in 
the number of patients with chronic diseases is 
accompanied by the growth of the health care 
expenditures. Hence, health care systems have to live up 
to the challenges imposed by the continuously changing 
economic environment, which is becoming even more 
hectic in the recent years. The satisfaction of patients as 
conscious purchasers has become the main goal.  
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Thus the introduction and continuous development of 
biologicals speeded up health economic research 
worldwide. The key questions are whether efficacy, cost-
effectiveness and budget impact results can be transferred 
between jurisdictions of Europe and what lessons can a 
country like Hungary with limited capacity for health 
economic analyses learn from these. There is limited data 
on the above mentioned topics in Hungary and in the 
CEE region and the proportion of patients treated with 
biological vary significantly between the countries. 
Therefore with this dissertation inter alia I would like to 
provide country specific data and analysis to expand the 
relevant literature. Here should be mentioned that in 
order to plan interventions, data-supported facts derived 
from well-established, reproducible, reliable analysis are 
necessary. 
Therefore, the purpose of this dissertation was to provide 
more knowledge and insight on this topic in the CEE 
region, focusing mainly on Hungary, by exploring 
evidences using methods from the field of health 
economics and health technology assessment. Although 
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this dissertation was mainly focused on Hungary, its 
relevance is not exclusive to the Hungarian context: the 
topic is also relevant for other countries facing similar 
challenges with the introduction of biological treatments, 
especially in the CEE region. 
The dissertation was written in manuscript based style 
and chapters are organised around the main objectives. 
The body of this dissertation comprises five autonomous 
publications. Chapters treat separate elements of my 
research program and include four discrete articles 
(which have been published in peer reviewed journals) 
and a book chapter. The first chapters (Chapter 1, 2 and 
3) state the research questions and describe the 
theoretical background of the thesis and integrate the 
thesis across the different manuscripts. Chapter 4 
presents a book chapter and an article, both of these deal 
with the statistical analysis of efficacy and safety of 
biologicals from a different point of view. Chapter 5 
presents a non-interventional, cross-sectional survey in 
the topic of economic burden regarding Psoriasis in 
Hungary. Chapter 6 continues with the topic of 
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Psoriasis, analysing the relationship between utility and 
standard Psoriasis related quality of life scales. Chapter 
7 presents data on the budget impact implied by the 
reimbursement of biosimilar infliximab over three years 
in six CEE countries. The last, concluding chapter 
(Chapter 8) includes a discussion on how the findings of 
the thesis provide a distinct contribution to knowledge in 
the research area. 
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II. Methods 
 
 
In this section I present the applied methods within each 
chapter of the thesis.  Chapter 4 of the thesis presents a 
book chapter and an article about the efficacy and safety 
of biologicals in Psoriatic Arthritis (PsA) and in 
Ankylosing Spondylitis (AS). We conducted a 
quantitative review on efficacy and safety of the 
biologicals based on a systematic literature review for 
randomised controlled trials (RCT). In this chapter a 
direct meta-analysis and mixed treatment comparison 
was performed. In the direct comparison: the relative 
risk, rate difference, numbers needed to treat and 
appropriate 95% CI were derived for each study 
according to the number of events reported in the original 
studies. Under the mixed treatment comparison we 
examined the relative effectiveness of each individual 
treatment using a mixed treatment comparisons model in 
a Bayesian framework.  
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Chapter 5 presents an article related to the cost-of-
illness (COI) of patients with moderate to severe 
Psoriasis in Hungary. We conducted a non-
interventional, cross-sectional questionnaire survey in 2 
university dermatology clinics in Hungary. Patients 
included in the research completed a set of questions in 
which demographic data, employment status, disease 
duration, self-assessed disease activity on a visual 
analogue scale (VAS) and Psoriasis related treatments 
were surveyed. Psoriasis related outpatient care 
utilisations, hospitalisations and transportation to attend 
medical care in the previous 12 months were also 
recorded. Informal care was assessed for the past month. 
Absence from work and reduced work productivity were 
captured by the Work Productivity and Activity 
Impairment questionnaire. Three subgroups were created 
after sampling based on patients’ psoriasis treatment at 
the time of the survey: patients not receiving systemic 
therapy (NST); patients receiving traditional systemic 
treatment (TST) and patients on biological systemic 
treatment (BST). We measured both the direct medical 
and non-medical costs, and also indirect costs with 
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Human Capital Approach (HCA) and with Friction Cost 
Approach (FCA). 
Based on the same study as in Chapter 5, Chapter 6 
presents an article which analysed the relationship 
between utility (measured by the EQ-5D) and disease 
specific quality of life and clinical scales (Dermatology 
Life Quality Index (DLQI) and Psoriasis Area and 
Severity Index (PASI)) in Psoriasis. Spearman’s rank 
correlation was used to test association between the 
above mentioned outcome measures. Mann–Whitney U-
test was performed to compare the differences in the 
distribution of EQ-5D, DLQI, and PASI. The known-
groups method was applied to compare outcome 
measure’s ability to detect differences between groups 
with known attributes.  
Chapter 7 presents the estimated budget impact of the 
introduction of biosimilar infliximab in rheumatoid 
arthritis (RA) over a three year time period in six selected 
countries, Bulgaria, the Czech Republic, Hungary, 
Poland, Romania and Slovakia. A prevalence based 
country-specific budget impact model was developed for 
RA. Two extreme scenarios were used: Biosimilar 
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scenario 1 (BSc1): Changing originator infliximab with 
biosimilar infliximab was disallowed. Only patients 
starting a new biological therapy were allowed to use 
biosimilar infliximab. Biosimilar scenario 2 (BSc2): 
Changing of originator infliximab with biosimilar 
infliximab was allowed after 6 months from treatment 
start, and originator infliximab is changed by biosimilar 
infliximab in 80% of patients. Also patients starting a 
new biological therapy were allowed to receive 
biosimilar infliximab as first line therapy. Finally, one-
way sensitivity analysis was performed changing 
different parameters of the model by ±10%: the 
assumption on the acquisition cost of biosimilar 
infliximab, the size of the initial population and its 
growth rate over time, the discontinuation rates of 
biological drugs and the rate of interchanging from 
infliximab to biosimilar infliximab. 
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III. Results 
 
My dissertation is among the first papers to provide data 
on chronic diseases involving patients with biological 
treatment. This dissertation therefore seeks to deal with a 
synthetised knowledge about the implementation of 
biotechnological therapies, using methods related to 
health economics.  
 
The following section states the main hypothesis, 
objectives and results of the dissertation, along with the 
relevant policy implications and limitations. 
 
Hypothesis 1: a) In case of PsA, biologicals are nearly 
similar and tolerable, b) in case of AS, the efficacy 
and safety of the new and original drug are both more 
beneficial than the treatment with placebo.   
 
Objective 
Some biologicals have been approved by the European 
Medicine Agency (EMA) for the treatment of adults with 
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severe, active AS and PsA. Furthermore, in September 
2013, the first biosimilar therapy, namely infliximab-
biosimilar was licensed in the EU for the first time for the 
treatment of AS. According to our knowledge, no meta-
analysis have been published yet in AS, which compares 
the efficacy and safety of the infliximab-biosimilar 
treatment to the other biological drugs indicated in AS.  
  
Results  
In the first book chapter we dealt with a quantitative 
review on efficacy and safety of the drugs in PsA based 
on 7 RCTs. Our quantitative review delivered both direct 
and indirect comparisons of the efficacy and safety of 
four biologics for PsA from double-blind, placebo-
controlled trials. However, one biological (adalimumab) 
was significantly less effective on achieving PsARC1 
response than the others. We conclude that the first part 
of the hypothesis was partially right, because every 
biological showed similar efficacy except one (as 
summarised on Figure 1). Regarding AS we can say that 
                                                 
1 The PsARC was developed as a PsA-specific composite responder 
index 
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this was the first study to include a biosimilar drug in the 
meta-analysis of biological treatments in AS. The results 
showed similar efficacy and safety profile of infliximab-
biosimilar treatment compared to other biologicals (as 
shown on Figure 2), proving the second part of the 
hypothesis. 
 
 
Figure 1. Statistical analysis and indirect comparison of 
efficacy of biologicals in clinical studies  
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Policy implications  
Transferability of efficacy and safety results from 
researches conducted in one country to another needs 
further consideration. This is especially relevant for the 
CEE countries that are characterised by particular 
economic conditions, health and social care systems. 
With these data we can provide input for further analysis. 
Biosimilar infliximab has the same effect as the existing 
drugs, and it is also cheaper than the existing biologicals 
in the market, therefore cost saving can be achieved, 
evidencing the appropriateness to choose this drug. 
 
Limitations  
A potential weakness of the meta-analyses arises from 
the fact that the trials from which data are combined are 
likely to differ in their design and patient population 
characteristics. 
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Figure 2. Statistical analysis and indirect comparison of 
safety of biologicals in clinical studies (serious adverse 
event) 
 
 
 
Explanation of the figure: Results for week 30 were available 
and considered for infliximab-biosimilar. Note: The figure 
presents odds ratios (OR) between treatments. If the point 
estimate is lower than 1 then the biosimilar treatment is safer 
(although not necessarily statistically significantly safer). 
Credibility intervals provide information on whether the 
difference between treatments is statistically significant. If the 
CI contains the value 1, the difference is not statistically 
significant. 
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Hypothesis 2: The treatment with biological therapies 
causes a significant financial burden to the society 
and the treatment of patients with these agents results 
in higher financial costs compared to the case without 
biological therapy. 
 
Objective  
My second objective was to assess the COI of patients 
with moderate to severe Psoriasis in Hungary, based on a 
cross-sectional survey in Hungarian dermatological 
centers. We analysed the results from a non-
interventional, cross-sectional questionnaire survey in 2 
university dermatology clinics in Hungary.  
 
Results  
The majority of the patients (N=103, 52%) received 
biological agent at the time of the assessment. According 
to the latest available data of National Health Insurance 
Found Administration, in 2010 altogether 682 patients 
with Psoriasis received biological treatment in Hungary; 
thus our survey captured a substantial proportion of this 
21 
 
patient group. The mean annual total cost per patient with 
HCA and FCA was €9,254 (SD €8,502) and €8,305 (SD 
€7,705), respectively, with direct costs accounting for 
86% and 96%. The main cost driver was the biological 
drug cost amounting to mean €7,339/patient/year in the 
total sample (N=200). Average total cost differed 
significantly between treatment subgroups (NST, TST 
and BST) both with HCA and FCA (p<0.001). Taking 
into account that the first biological agent was registered 
for the treatment of Psoriasis in 2004 we would have 
expected COI studies analysing patients with biological 
treatment by the end of January 2010, the date when the 
last systematic literature review was closed. Contrarily, 
no such studies had been published by that time. 
Therefore, we performed a literature search for COI 
studies for the period from January 2010 to December 
2013 using the same search terms and databases as it was 
in a previous study. Our search identified nine 
publications (results can be seen in Table 1), seven of 
which involved Psoriasis patients with biological 
treatment. We fund that the total costs of treatment with 
biologicals were higher compared to our results in 
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Hungary almost all cases. In three studies the costs of 
hospitalization and out-patient visits were lower in 
biological treated subgroups, similarly to our findings. In 
line with our hypothesis, biological treatment increased 
the direct costs associated with Psoriasis while 
considerably improved quality of life of patients, so the 
hypothesis was right. Our study was the first from the 
CEE region to provide COI data and had the largest 
sample size of biologic treated patients in Europe. 
 
Policy implications  
Our study showed that the economic burden of Psoriasis 
is considerable in Hungary, however comparing to 
international data we observe lower costs in Hungary. 
With this study we provided input for further health 
economic analyses and a baseline to evaluate the 
economic effects of Psoriasis treatment in Hungary. 
These information are useful for medical decision 
making, developing guidelines and value based 
reimbursement. 
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Limitations  
The survey was conducted in two university based 
dermatology centres involving Psoriasis patients 
attending outpatient care. Patients with mild Psoriasis 
were not selected and patients with severe Psoriasis 
might be under-represented in the sample. We used a 
retrospective survey to assess health care utilisations, 
recall bias might be present. Another limitation is due to 
the cross-sectional design; the current treatment was used 
as a proxy to measure disease severity and costs.
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Table 1. Cost-of-illness studies of Psoriasis, reporting costs of biological treated patients 
(BST), till December 2013 in comparison with results of the current survey 
 
Study Method Patients Ntotal/ 
Nbiologic 
Mean direct 
cost/patient/year 
TST / BST 
Mean indirect 
cost/patient/year 
TST / BST 
Mean total 
cost/patient/year 
TST / BST 
Fonia et al. 
2010, United 
Kingdom 
retrospective 
chart review  
severe Psoriasis, 2 
tertiary dermatology 
centers 
76/76 €4,742 / €13,505 n.r. n.a. 
Driessen et a. 
2010, The 
Netherlands 
retrospective 
chart review 
moderate to severe 
Psoriasis, 1 tertiary 
dermatology center 
67/67 €10,146 / 
€17,712 
n.r. n.a. 
Ghatnekar et 
al. 2012, 
Sweden 
follow-up 
study 
severe Psoriasis, 1 
tertiary and 1 secondary 
dermatology center  
164/27 €7,812/ €18,457 €5,208/ €2,051 €13,020/ €20,508 
Le Moigne et 
al. 2013, 
France 
insurance claim 
database 
analysis 
general Psoriasis 
population, all types of 
out-patient and 
inpatient providers in 
1,924/69 €3,356 / €16,214 n.r. n.a.  
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Study Method Patients Ntotal/ 
Nbiologic 
Mean direct 
cost/patient/year 
TST / BST 
Mean indirect 
cost/patient/year 
TST / BST 
Mean total 
cost/patient/year 
TST / BST 
an administrative area 
Balogh et al. 
2014, Hungary 
(current 
survey) 
cross-sectional 
study 
moderate to severe 
Psoriasis at 2 tertiary 
dermatology centers 
200/103 €1,428/ €14,363 €960 / €1,427 €2,388/ €15,790 
n.r.: not reported; n.a.: not applicable 
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Hypothesis 3: Generic and disease specific quality of 
life scales and disease severity scores correlate with 
utilities. 
 
Objective 
According to literature search there was no data based on 
empirical research from the CEE region regarding 
biological treated patients in Psoriasis. Our study was the 
first research in this topic. My third objective was to 
provide data regarding utility and quality of life of 
Psoriaris patients, contributing to the international 
literature. Further objectives were to analyse the utilities 
between general and disease specific scales and disease 
severity measurement in Psoriasis and to transform 
scores, key clinical, demographic and health service 
utilisation variables into utility measures. 
 
Results  
This study provided the first evidence that patients with 
visible psoriatic lesions have significantly worse health 
related quality of life (HRQOL) compared to those with 
non-visible lesions, measured not just only with disease 
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specific questionnaire DLQI but also with a general 
questionnaire, EQ-5D. In addition to demographic and 
clinical variables, our model included health service 
utilisation variables related to Psoriasis, and explained 
higher proportion of EQ-5D variance than any previous 
findings in the literature (see in Table 2). EQ-5D score 
showed a moderate negative correlation with DLQI, 
PASI and with patients self-assessed disease severity 
VAS (0.29 < rs < 0.5). Strong significant correlation was 
found between DLQI, PASI, and self-assessed disease 
severity VAS. The models are explaining 48.8% of EQ-
5D variance (adjusted R2=0.488, ANOVA p<0.001), so 
the hypothesis was approved. 
 
 
Table 2. Regression coefficients in the multivariate 
mapping on EQ-5D  
 
 EQ-5D score 
 
Unstandardised 
regression 
coefficient 
Standardised 
regression 
coefficient 
P 
Constant 1.026  <0.001 
Age - - - 
Gender (female) -0.090 -0.145 0.014 
BMI - - - 
Psoriasis 
duration 
-0.004 -0.169 0.006 
DLQI -0.080 -0.190 0.023 
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 EQ-5D score 
 
Unstandardised 
regression 
coefficient 
Standardised 
regression 
coefficient 
P 
Self-assessed 
disease severity 
VAS 
- - - 
Chronic plaque 
Psoriasis 
-0.089 -0.151 0.029 
Palmoplantar 
Psoriasis 
-0.347 -0.269 <0.001 
Scalp Psoriasis 0.152 0.252 0.001 
Psoriatic 
arthritis 
-0.134 -0.212 0.002 
GP visit(s) due to 
Psoriasis in the 
last month 
-0.160 -0.227 <0.001 
Hospitalisation(s) 
due to Psoriasis 
in the last 12 
months 
-0.104 -0.160 0.013 
Use of home help 
(professional or 
informal) in the 
last month 
-0.139 -0.160 0.021 
 
 
 
Policy implications  
This study confirmed previous findings about 
correlations between questionnaires and quality of life 
scores. Due to biologicals, HRQOL measures should be 
able to face a new patient population with better health 
state, with currently unexplored possible predictors of 
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HRQOL and with new expectations of treatment 
outcomes. Furthermore, cost-effectiveness analyses 
require input data both on effectiveness in terms of health 
gain (considering the quality of the life years gained and 
utilities) and disease related costs on the social level.  
 
Limitations  
To our knowledge, HRQOL median values of our sample 
were reflecting better health states than in other previous 
cross-sectional surveys. This might be the result of the 
biological treatment received by about half of our 
patients and may also be due to the treatment institutions, 
which were two university clinics considered to offer 
higher quality of care. Additionally, several limitations of 
mapping should be noted.  
 
 
 
 
 
 
 
 
 
30 
 
Hypothesis 4: The introduction of biosimilar 
infliximab leads to substantial savings in health care 
budgets. 
 
Objective 
The first biosimilar monoclonal antibody (biosimilar 
infliximab) was registered by the EMA in 2013 for the 
treatment of several inflammatory conditions including 
RA and AS. Biosimilar infliximab is first marketed in the 
CEE countries. My fourth aim was to build a model to 
perform budget impact analysis of biological therapies in 
six CEE countries for 3 years within RA.  
 
Results  
In 2013, approximately 17,300 RA patients were treated 
with biological drugs in the six CEE countries. Findings 
showed that in BSc1 the introduction of biosimilar 
infliximab in the biologic treatment setting led to a total 
savings of €15.3 M in the first three years of its 
introduction. Allowing for changing of original 
infliximab to biosimilar infliximab had a significant 
impact on budget savings. In BSc2 the total saving was 
estimated to be €20.8 M (see in Table 3) over the three 
years. The cost savings may be reinvested to treat 
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additional patients with biological drugs. If all budget 
savings were spent on reimbursing biological therapy of 
new patients with biosimilar infliximab, an additional 
1,205 patients in BSc1 or 1,790 patients in BSc2 could be 
treated with biological drugs after three years. According 
to the results of the sensitivity analysis, the number of the 
initial population treated with biological agents and the 
assumption on the acquisition cost of biosimilar were the 
two main cost drivers (20.1% and 18.6%) in the model. 
 
Policy implications  
This was the first study to estimate the budget impact of 
introducing the first biosimilar (infliximab) in the CEE 
countries. The analysis was carried out with multiple 
scenarios in order to evaluate various assumptions. Our 
analysis has shown that introducing biosimilar infliximab 
as a treatment for RA might result in considerable budget 
savings. Based on the present analysis, the introduction 
of biosimilar infliximab as an alternative treatment option 
for RA in CEE was predicted to bring substantial cost 
savings to the national health care budget. Based on these 
results, the use of biosimilar infliximab appeared to be 
economically attractive because it offers the potential to 
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reduce the total expenditures or to increase the number of 
patients treated on a fixed budget with biologicals.  
 
 
Furthermore, biosimilar infliximab has the same effect as 
the existing drugs with the additional benefit of cost 
saving, therefore it is appropriate to choose this drug. 
 
 
Table 3. Results of the scenario analyses 
 Budget impact (euro) Number of new RA 
patients  on 
biological treatment 
if budget savings 
would be spent on 
biosimilar 
infliximab 
 year 1 year 2 year 3 Total 
year 
1 
year 
2 
year 
3 
Biosimi
larScen
ario 1 
-
945,241 
-
4,782,4
62 
-
9,612,3
31 
-
15,340,
034 
165 672 
1,20
5 
Biosimi
lar 
Scenari
o 2 
-
2,394,5
45 
-
6,968,6
20 
-
11,463,
059 
-
20,826,
224 
242 1,002 
1,79
0 
Biosimilar scenario1: interchanging of biosimilar and 
original biologicals is not allowed  
Biosimilar scenario2: interchanging of biosimilar and 
original biologicals is allowed at least six months after 
treatment start 
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Limitations  
Due to the number of limitations of this budget impact 
analysis the results should be interpreted with caution. 
First, it should be taken into account, that any model is a 
simplification of the real treatment process. The model 
collected only resource use and costs for an average 
patient and did not consider other factors such as disease 
severity, patient characteristics or other disease-related 
factors. The model did not account for the changes in 
indirect societal costs arising from absence from work. 
Another limitation is that a dynamic cohort approach was 
applied in the study as in each model cycle some patients 
left the model while new patients entered it. 
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